OSE Immunotherapeutics

Declaration of Voting Results & Voting Rights Announcements • Sep 6, 2016

Total number of voting rights and shares

Nantes, Paris, September 6, 2016 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority), OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), a biotechnology company developing immunotherapies of activation or regulation in immuno-oncology, auto-immune diseases and transplantation, informs its shareholders of the number of voting rights and shares on the date of August 31, 2016.

Date	Total number of outstanding shares	Total number of voting rights
August, 31, 2016	14.250.753	Theoretical1 : 14.250.753 Exercisable : 14.220.238

¹ Theoretical voting rights = total number of voting rights attached to the total number of shares, including treasury shares and private voting shares.

ABOUT OSE IMMUNOTHERAPEUTICS

A world leader in activation and regulation immunotherapies

OSE immunotherapeutics is a biotechnology company focusing on immune regulation in immuno-oncology, auto-immune diseases and transplantation, with a peak immunologist team to develop activation and regulation immunotherapies.

The company has a balanced portfolio of first-in-class products, with a diversified risk profile, ranging from the clinical phase registration to R&D :

• Tedopi®, combination of 10 optimized neo-epitopes to induce a specific T activation in immuno-oncology currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan Status in the US - registration expected in 2019
• FR104, CD28-antagonist in immunotherapy Phase 1 trial completed targets autoimmune diseases and transplantation licensed to J&J to pursue clinical development
• Effi-7, interleukin receptor 7 antagonist in preclinical stage for inflammatory bowel diseases and other autoimmune diseases
• Effi-DEM, new generation checkpoint inhibitor targeting receptor SIRP-α on strategic pathway CD47/SIRP- α - in preclinical stage for immuno-oncology
• R&D: candidates targeting new receptors in immuno-oncology

Given the targeted medical needs, these products show a real potential of blockbuster and give the company the ability to enter into global agreements at different stages of development with major pharmaceutical actors, such as the one signed on FR104 product with the J&J Group.

OSE Immunotherapeutics aims for the field of immunotherapy, a highly promising growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at \$ 67 billion in 2018 **.

There are more than 80 autoimmune diseases that represent a significant market including major actors in the pharmaceutical industry with sales upper 10 billion \$ for the main products. The medical need remains today highly unmet and requires the provision of new innovative and suitable products involved in the regulation of the immune system.

*Citi Research Equity **BCC Research

From September 1st, 2016, the new company's headquarter is located: 22, boulevard Benoni Goullin, 44200 Nantes, France

Contacts

OSE Immunotherapeutics Dominique Costantini, CEO dominique.costantini@ose-immuno.com Mob +33 6 13 20 77 49

Maryvonne Hiance, Vice-Présidente maryvonne.hiance@ose-immuno.com Tél : +33 (0) 240 412 834 Mobile : 33 (0) 680 060 183

Alexis Peyroles, DGD, Operations, Finance & BD alexis.peyroles@ose-immuno.com Mob : +33 6 11 51 19 77

Bernard Vanhove, DGD, R&D, Collaborations scientifiques Bernard.vanhove@ose-immuno.com Mob: +33 6 75 41 40 08

Contacts media Citigate Dewe Rogerson Laurence Bault laurence.bault@citigate.fr +33 1 53 32 84 78

Alize RP Florence Portejoie & Caroline Carmagnol oseimmuno@alizerp.com +33 6 47 38 90 04

Consilium Strategic Communications Chris Gardner / Matthew Neal / Hendrik Thys OSEImmuno@consilium-comms.com +44 (0) 20 3709 5700

Rx Communications Group, LLC Melody Carey mcarey@rxir.com + 1 917-322-2571

Acorelis Gilles Petitot Mobile : 33 (0) 620 27 65 94 gilles.petitot@acorelis.com